clinical effectiveness , considered as 70 -- 80 % reduction of total number of pvcs , was obtained in 8/12 patients for propafenone and 6/12 for disopyramide , or as 50 % reduction with suppression of all complex pvcs ( couplets , repetitive , multiform and bigeminy ) was obtained in 11/12 for propafenone and 9/12 for disopyramide .
C0151636
complex pvcs
C0012702
disopyramide